Elicera Therapeutics AB (publ) (STO:ELIC)
2.465
+0.025 (1.02%)
Nov 20, 2026, 5:25 PM CET
Elicera Therapeutics AB Revenue
Elicera Therapeutics AB had revenue of -147.66K SEK in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to 7.79M, up 29.45% year-over-year. In the year 2025, Elicera Therapeutics AB had annual revenue of 10.86M with 52.28% growth. That makes Elicera Therapeutics AB the 44,042nd largest company in the world by revenue and 690th in Sweden.
Revenue (ttm)
7.79M
Revenue Growth
+29.45%
P/S Ratio
21.11
Revenue / Employee
2.60M
Employees
3
Market Cap
164.51M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.86M | 3.73M | 52.28% |
| Dec 31, 2024 | 7.13M | -4.10M | -36.52% |
| Dec 31, 2023 | 11.23M | 9.95M | 777.23% |
| Dec 31, 2022 | 1.28M | 1.28M | 217,987.39% |
| Dec 31, 2021 | 587.00 | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 750.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xbrane Biopharma AB | 127.95M |
| IRLAB Therapeutics AB | 71.79M |
| BioInvent International AB | 39.98M |
| Intervacc AB | 17.35M |
| Abera Bioscience AB | 5.66M |
| Xintela AB | 3.03M |
| Simris Group AB (PUBL) | 1.14M |
| Diamyd Medical AB | 477.00K |
Elicera Therapeutics AB News
- 5 weeks ago - Elicera Therapeutics AB Press release: Study update - Filings
- 2 months ago - Elicera Therapeutics AB Quarterly report: Q2 2026 - Filings
- 6 months ago - Elicera Therapeutics AB Press release: Status update - Filings
- 7 months ago - Elicera Therapeutics AB Quarterly report: Q1 2026 - Filings
- 9 months ago - Elicera Therapeutics AB Quarterly report: Q4 2025 - Filings
- 9 months ago - Elicera Therapeutics AB Annual report: Q4 2025 - Filings